Patient-derived organoids predict treatment response in metastatic colorectal cancer

Accurately predicting treatment response in metastatic colorectal cancer (mCRC) is critical to avoid unnecessary toxicity and improve patient outcomes. A multicenter study in The Netherlands evaluated patient-derived organoids (PDOs) as predictors of treatment response in mCRC. Interim analysis of the study found that the 5-FU & oxaliplatin PDO screens demonstrated high predictive accuracy and were associated with progression-free survival and overall survival. The authors concluder that PDOs can accurately predict patient outcomes during systemic treatment.